Sadatsafavi, Mohsen - University of British Columbia - Faculty of Pharmaceutical Sciences

个人简介

I am an epidemiologist and health outcomes scientist. I lead the Respiratory Evaluation Sciences Program (http://resp.core.ubc.ca) within the Collaboration for Outcomes Research and Evaluation, UBC Faculty of Pharmaceutical Sciences. I received MD degree from Tehran University of Medical Sciences in 2002, MHSc degree in Epidemiology from The University of British Columbia in 2007, and PhD degree in Health Economics and Outcomes Research from The University of British Columbia in 2012. In addition to my primary appointment, I hold affiliations with the Centre for Clinical Epidemiology and Evaluation as well as the Division of Respiratory Medicine, UBC. For my research related to the RESP program, I have received Canadian Institutes of Health Research’s New Investigator Salary Award and Michael Smith Foundation for Health Research’s Scholar Award.

研究领域

RESP is a comprehensive epidemiology/outcomes research program in respiratory medicine with the aim of improving patient outcomes and the efficiency of health care delivery through evidence-informed decision making at all levels of care. To achieve this goal, RESP uses innovative techniques in health economics and outcomes research. A distinct feature of RESP is its dual focus: it generates new knowledge on the extent of the burden, gaps in care, and 'real world' effectiveness of treatments (Theme 1, Burden of Disease and Observational Effectiveness Research); it also concentrates on economic evaluations that translate such knowledge into policy-relevant, actionable messages (Theme 2, Evaluation). Together, these synergistic themes complete a logical pathway that answers the key questions: 'How big is the problem?', 'What are the options to tackle the problem?', and, 'What option provides the best health and economic return on investment?'. Integrated Knowledge Translation activities based on a Policy-Practice-Research partnership ensure that our research results in meaningful improvements in patient care and outcomes. Through our Theme 1 research, RESP emerged as a leader in quantifying the burden of respiratory diseases in Canada. We have performed in-depth analyses of administrative health databases to estimate the real-world direct costs of asthma, and conducted complementary clinical studies to assess its impact on quality of life and productivity loss. We have used high quality, population-based databases of British Columbia to document poor adherence to asthma medications resulting in suboptimal asthma control in the province, and have suggested potentially cost-effective solutions that are currently being evaluated in a randomized clinical trial. Our research in Theme 2 applies principles of economic evaluation, a systematic approach in translating the evidence into actionable messages on cost-effectiveness. This is typically done through decision-analytic modeling. We have completed a large number of modeling projects and have vast experience in this area and have contributed in major ways to methodology in this field.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Individualizedpredictionoflung-functiondeclineinchronicobstructivepulmonarydisease,Zafari,Z.,SinD.D.,PostmaD.S.,LofdahlC.-G.,VonkJ.,BryanS.,LamS.,TammemagiC.M.,KhakbanR.,ManS.F.P.,etal.,CanadianMedicalAssociationJournal,Apr-10-2016,Volume188,Issue14,p.1004-1011,(2016) TheAssociationBetweenRateandSeverityofExacerbationsinChronicObstructivePulmonaryDisease:AnApplicationofaJointFrailty-LogisticModel,Sadatsafavi,Mohsen,SinDonD.,ZafariZafar,CrinerGerard,ConnettJohnE.,LazarusStephen,HanMeilan,MartinezFernando,andAlbertRichard,AmericanJournalofEpidemiology,Jan-11-2016,Volume184,Issue9,p.681-689,(2016) Dispensationoflong-actingagonistswithorwithoutinhaledcorticosteroids,andriskofasthma-relatedhospitalisation:apopulation-basedstudy,Sadatsafavi,M.,LyndL.D.,MarraC.A.,andFitzGeraldJ.M.,Thorax,Jan-04-2014,Volume69,Issue4,p.328-334,(2014) NeedforSpeed:AnEfficientAlgorithmforCalculationofSingle-ParameterExpectedValueofPartialPerfectInformation,Sadatsafavi,Mohsen,BansbackNick,ZafariZafar,NajafzadehMehdi,andMarraCarlo,ValueinHealth,Jan-03-2013,Volume16,Issue2,p.438-448,(2013) Comparativeoutcomesofleukotrienereceptorantagonistsandlong-actingβ-agonistsasadd-ontherapyinasthmaticpatients:Apopulation-basedstudy,Sadatsafavi,Mohsen,LyndLarry,MarraCarlo,BedouchPierrick,andFitzGeraldMark,JournalofAllergyandClinicalImmunology,Jan-07-2013,Volume132,Issue1,p.63-69,(2013)